Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Pharmacokinetics
59%
Tenofovir
54%
Dapivirine
21%
Emtricitabine
21%
Human Immunodeficiency Virus Infection
21%
Tenofovir Disoproxil
20%
Cabotegravir
19%
Placebo
17%
Pharmacodynamics
16%
Clinical Trial
14%
Tenofovir Alafenamide
11%
Maraviroc
10%
Adverse Event
9%
Infection
9%
Drug Concentration
9%
Implant
8%
Fumaric Acid
8%
Microbicide
7%
Tolerability
7%
Levonorgestrel
6%
Glycerol
6%
Antiretrovirus Agent
5%
Randomized Controlled Trial
5%
Rifapentine
5%
Macaca
5%
Keyphrases
Pre-exposure Prophylaxis (PrEP)
38%
Tenofovir
28%
Pharmacokinetics
26%
HIV Pre-exposure Prophylaxis
19%
Tenofovir Disoproxil Fumarate
18%
Dapivirine
15%
HIV Research Network
14%
Cabotegravir
13%
Emtricitabine
13%
Human Immunodeficiency Virus Type 1 (HIV-1)
12%
AIDS/HIV
12%
HIV Patients
11%
Vaginal Ring
10%
Antiviral Drugs
10%
HIV Infection
9%
Maraviroc
9%
Transgender
9%
Pharmacodynamics
9%
Tenofovir Alafenamide
8%
Drug Concentration
8%
Oral Pre-exposure Prophylaxis
7%
Dapivirine Vaginal Ring
7%
Cisgender
7%
Fumarate
7%
Placebo
6%
Long-acting Injectable
6%
Tolerability
6%
Men Who Have Sex with Men
6%
Adverse Events
6%
Tenofovir Diphosphate
6%
Human Immunodeficiency Virus Infection
6%
Human Immunodeficiency Virus Prevention
5%
United States
5%
Long-acting Cabotegravir
5%
Safety Study
5%
Pharmacokinetic Study
5%
Antiretroviral
5%
HIV Prevention
5%